GlassScriptPhysician profile
Graham C Scott
NPI 1265481303
$353.77
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.94 · 2020: $51.80 · 2021: $137 · 2022: $57.75 · 2023: $16.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $173.94 | 2021-2022 | |
| Glaxosmithkline, LLC. | $51.96 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $44.25 | 2019-2020 | |
| Intuitive Surgical, INC. | $20.44 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.03 | 2020 | |
| Gilead Sciences, INC. | $16.65 | 2023 | |
| Mylan Specialty L.P. | $16.06 | 2019 | |
| Nabriva Therapeutics, Plc | $11.44 | 2020 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$100.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graham Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.